RDNT RadNet, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 790526 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.1%
TTM net income YoY-76.1%
TTM EPS YoY-81.3%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin3.1%
Net margin-0.9%
FCF margin—
EBITDA margin10.6%
Returns
ROE-2.1%
ROA-0.6%
ROIC (approx.)2.8%
Asset turnover0.60x
Leverage & solvency
Liabilities / assets66.4%
Debt / equity1.18x
Current ratio1.49x
Interest coverage0.99x
Cash quality & payout
Operating cash flow / net income-15.54x
Accruals ratio-9.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $638.26M | $622.72M | $575.63M | $547.71M | $522.87M | $498.23M | $471.40M | $477.10M |
| Operating income | $30.26M | $39.47M | -$23.90M | $27.82M | $27.39M | $30.88M | -$24.10M | $24.52M |
| Interest expense | $20.68M | $18.15M | $17.66M | $18.13M | $17.36M | $17.19M | $17.24M | $18.07M |
| Pretax income | $27.51M | $26.62M | -$32.83M | $20.92M | $20.27M | $23.85M | -$33.13M | $15.32M |
| Income tax | $8.36M | $6.36M | -$8.10M | $11.05M | $6.38M | $820,000 | -$3.40M | $1.10M |
| Net income | $4.15M | $7.53M | -$33.47M | -$597,000 | $5.42M | $14.45M | -$37.93M | $5.34M |
| EBITDA | $77.27M | $85.00M | $21.06M | $68.68M | $67.19M | $66.87M | $11.38M | $60.54M |
| EPS (basic) | 0.05 | 0.10 | -0.43 | — | 0.07 | 0.19 | -0.51 | — |
| EPS (diluted) | 0.05 | 0.10 | -0.43 | — | 0.07 | 0.19 | -0.51 | — |
| Weighted avg. shares (diluted) | 79.17M | 78.73M | 77.06M | — | 77.39M | 75.53M | 74.38M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $750.61M | $726.27M | $455.34M | $767.22M | $804.72M | $833.15M | $717.32M | $740.02M |
| Receivables | $248.89M | $241.84M | $209.09M | $200.32M | $210.55M | $199.99M | $200.13M | $185.82M |
| Current assets | $1.07B | $1.04B | $740.77M | $1.03B | $1.08B | $1.09B | $1.02B | $1.02B |
| PP&E, net | $904.27M | $879.90M | $862.06M | $807.70M | $780.50M | $741.38M | $708.25M | $694.79M |
| Goodwill | $1.14B | $1.12B | $1.09B | $907.66M | $827.53M | $751.51M | $717.48M | $710.66M |
| Intangibles | $235.06M | $245.35M | $253.48M | $148.51M | $124.91M | $91.08M | $79.74M | $81.35M |
| Total assets | $4.28B | $4.23B | $3.89B | $3.76B | $3.67B | $3.51B | $3.34B | $3.29B |
| Current liabilities | $716.64M | $697.82M | $635.63M | $586.76M | $574.91M | $546.21M | $505.40M | $479.71M |
| Short-term debt | $31.80M | $30.67M | $26.51M | $25.42M | $25.45M | $25.48M | $24.68M | $24.69M |
| Long-term debt | $1.29B | $1.30B | $1.06B | $1.06B | $1.07B | $1.08B | $985.45M | $991.57M |
| Total debt | $1.33B | $1.33B | $1.09B | $1.09B | $1.10B | $1.10B | $1.01B | $1.02B |
| Total liabilities | $2.84B | $2.83B | $2.53B | $2.40B | $2.35B | $2.34B | $2.20B | $2.15B |
| Shareholders' equity | $1.12B | $1.10B | $1.08B | $1.09B | $1.06B | $932.31M | $898.14M | $902.31M |
| Net debt | $574.69M | $606.26M | $631.14M | $322.70M | $291.62M | $269.58M | $292.81M | $276.25M |
| Shares outstanding | 78.77M | 78.65M | 78.55M | 77.40M | 77.03M | 75.07M | 74.96M | 74.04M |
| Cash flow statement | ||||||||
| Operating cash flow | $90.57M | $94.10M | $78.97M | $84.16M | $52.83M | $120.35M | $41.48M | $42.53M |
| Investing cash flow | -$53.09M | -$63.55M | -$370.97M | -$113.94M | -$75.72M | -$97.45M | -$56.75M | -$48.81M |
| Financing cash flow | -$12.84M | $240.22M | -$17.50M | -$7.39M | -$5.32M | $92.43M | -$7.51M | -$2.12M |
| Depreciation & amortization | $47.01M | $45.53M | $44.97M | $40.85M | $39.80M | $35.99M | $35.48M | $36.02M |
| Stock-based compensation | $10.02M | $10.54M | $31.38M | $8.32M | $9.04M | $8.74M | $28.49M | $8.46M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.